Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
复制标题
DOI：
10.1093/jnci/djaa001
复制
发表时间：
2020-10-01
期刊：
影响因子：
--
通讯作者：
Etzioni R
中科院分区：
文献类型：
--
作者：
Heijnsdijk EAM;Gulati R;Tsodikov A;Lange JM;Mariotto AB;Vickers AJ;Carlsson SV;Etzioni R
在瑞典人群中进行的研究表明，44-50 岁和 60 岁前列腺特异性抗原 (PSA) 水平最低的男性未来因前列腺癌发生远处转移或死亡的风险非常低。本研究调查了按 PSA 水平分层的筛查策略的益处和危害。将前列腺癌进展、检测和死亡率的两个微观模拟模型的 PSA 水平和诊断模式与马尔默预防项目的结果进行比较，该项目存储血清并跟踪随后的前列腺癌诊断 25 年。这些模型预测了 PSA 分层筛查策略与 45 岁至 69 岁每两年一次筛查的危害（检测和过度诊断）和益处（挽救生命和延长生命年）。与 45-69 岁每两年进行一次筛查相比，延长 45 岁时 PSA 低于 1.0ng/mL 男性的筛查间隔可减少 46.8-47.0% 的检查（模型之间的范围），减少 0.9-2.1% 的过度诊断，并减少 3.1-3.8% 的挽救生命。当 60 岁及以上 PSA 低于 1.0ng/mL 时停止筛查，可减少 12.8-16.0% 的检查，减少 5.0-24.0% 的过度诊断，并减少 5.0-13.1% 的生命挽救。模型结果的差异部分可以通过对 PSA 增长与疾病进展风险之间联系的假设差异来解释。相对于两年一次的筛查策略，本研究中调查的 PSA 分层筛查策略大大减轻了检测负担，并适度减少了过度诊断，同时保留了大多数已挽救的生命。需要进一步研究来阐明 PSA 增长与疾病进展之间的联系。
Studies conducted in Swedish populations have shown that men with lowest prostate-specific antigen (PSA) levels at ages 44–50 years and 60 years have very low risk of future distant metastasis or death from prostate cancer. This study investigates benefits and harms of screening strategies stratified by PSA levels. PSA levels and diagnosis patterns from two microsimulation models of prostate cancer progression, detection, and mortality were compared against results of the Malmö Preventive Project, which stored serum and tracked subsequent prostate cancer diagnoses for 25 years. The models predicted the harms (tests and overdiagnoses) and benefits (lives saved and life-years gained) of PSA-stratified screening strategies compared with biennial screening from age 45 years to age 69 years. Compared with biennial screening for ages 45–69 years, lengthening screening intervals for men with PSA less than 1.0 ng/mL at age 45 years led to 46.8–47.0% fewer tests (range between models), 0.9–2.1% fewer overdiagnoses, and 3.1–3.8% fewer lives saved. Stopping screening when PSA was less than 1.0 ng/mL at age 60 years and older led to 12.8–16.0% fewer tests, 5.0–24.0% fewer overdiagnoses, and 5.0–13.1% fewer lives saved. Differences in model results can be partially explained by differences in assumptions about the link between PSA growth and the risk of disease progression. Relative to a biennial screening strategy, PSA-stratified screening strategies investigated in this study substantially reduced the testing burden and modestly reduced overdiagnosis while preserving most lives saved. Further research is needed to clarify the link between PSA growth and disease progression.
登录
查看更多内容
影响因子：
--
作者：
Aus, G;Damber, JE;Hugosson, J
通讯作者：
Hugosson, J
DOI：
10.1136/bmj.c4521
发表时间：
2010-09-14
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Vickers AJ;Cronin AM;Björk T;Manjer J;Nilsson PM;Dahlin A;Bjartell A;Scardino PT;Ulmert D;Lilja H
通讯作者：
Lilja H
DOI：
10.1056/nejmoa1311593
发表时间：
2014-03-06
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bill-Axelson A;Holmberg L;Garmo H;Rider JR;Taari K;Busch C;Nordling S;Häggman M;Andersson SO;Spångberg A;Andrén O;Palmgren J;Steineck G;Adami HO;Johansson JE
通讯作者：
Johansson JE
影响因子：
39.2
作者：
Gulati R;Gore JL;Etzioni R
通讯作者：
Etzioni R
影响因子：
6.4
作者：
Jonsson, Hakan;Holmstrom, Benny;Stattin, Par
通讯作者：
Stattin, Par